LIIBuy
Lennox International
Price (1y)
Recent regulatory events
- Auditor change (8-K Item 4.01)AnnotateView filing
Latest 8-K: 2025-03-13
Fair price check
6 different valuation methods each estimate what LII should be worth, then we compare to today's price.
- P/E multiplesUndervaluedthinks it's a bargain — estimates $634.75, about 27% above today
- EV/EBITDAFairthinks it's fairly priced — estimates $564.87, about 13% above today
- Residual IncomeOvervaluedthinks it's expensive — estimates $440.03, about 12% below today
- P/B multiplesOvervaluedthinks it's expensive — estimates $229.73, about 54% below today
- DCF (2-stage)Overvaluedthinks it's expensive — estimates $181.39, about 64% below today
- Graham (defensive)Outlierestimate looks unreliable — estimates $76.64 — likely unreliable
How to read this: “Cheap” = method's fair price is at least 20% above today. “Fair” = within ±10–20%. “Pricey” = at least 10% below today. Outliers (values more than 5× or less than 0.2× today's price) are excluded.
Fair price ensemble
| Method | Value |
|---|---|
| Graham (defensive) | $76.64 |
| P/E multiples(vs sector peers) | $634.75 |
| P/B multiples(vs sector peers) | $229.73 |
| EV/EBITDA(vs sector peers) | $564.87 |
| Residual Income | $440.03 |
| DCF (2-stage) | $181.39 |
- goodwill heavy
- extreme graham estimate
Median of all applicable methods (current price $499.99). Outliers above 5× or below 0.2× current price are excluded from the max but kept in the median. See methodology for the 6-method ensemble + 7 defenses.
Pillar breakdown
8 dimensions, each scored 0–100 against the universe
- QualityProfit margins & asset efficiency95Strong
- ValuePrice vs fundamentals58Decent
- GrowthRevenue & earnings trajectory80Strong
- MomentumRecent price strength24Poor
- HealthBalance sheet & solvency71Strong
- ProfitabilityROE, ROA, ROIC70Strong
- TechnicalTrend & volatility signals50Decent
- RiskVolatility & drawdown profile33Weak
Pillars not shown: Sentiment, ML (Phase 5+).
Raw fundamentals (SEC EDGAR)
| Metric | Value |
|---|---|
| Market cap | $17.40B |
| Revenue (TTM) | $5.26B |
| Net income (TTM) | $793.50M |
| Operating cash flow (TTM) | $809.50M |
| CapEx (TTM) | $148.80M |
| Free cash flow (TTM)CFO − CapEx | $660.70M |
| Total assets | $4.29B |
| Total liabilities | $3.08B |
| Stockholders' equity | $1.21B |
| Cash & equivalents | $48.20M |
| Shares outstanding | 34.80M |
| EPS (basic) | $3.37 |
| EPS (diluted) | $3.35 |
| P/E ratio (TTM) | 21.93 |
TTM = trailing twelve months. Balance sheet items are point-in-time (latest filing).
Data quality
- Latest filed date
- 2026-04-29
- Latest period end
- 2026-04-22
- Filing lag
- 17 days
- Missing metrics
- 3(research_and_development, accounts_receivable, long_term_debt)
Phase 3c — composite is the 8-pillar weighted score over quality, value, growth, momentum, health, profitability, technical, and risk. Sentiment + ML pillars land in Phases 5-6; until then their weight redistributes pro-rata. Fair price is the median of 6 valuation methods (Graham, P/E / P/B / EV-EBITDA multiples, RIM, DCF) with outliers above 5× current price excluded from the max. Risk-overlay flags annotate only — they suppress the entered-top-5 badge but do not modify the composite.